

Centre For AIDS Reagents

Data Sheet

REAGENT:	J-Lat Tat-GFP Cells (A7)
REPOSITORY REFERENCE:	100 945
LOT NUMBER:	150245
RELEASE RESTRICTIONS:	NIH Category C
PROVIDED:	1 mL at 4.7 x 10^6 cells/vial. 92% viability.
STORAGE:	Liquid nitrogen
DESCRIPTION:	These cells are Jurkat cells that bear the integrated retroviral construct LTR-Tat-IRES-GFP.
SPECIAL CHARACTERISTICS:	Jurkat cells were infected with viral particles bearing the retroviral construct LTR-Tat-IRES-GFP. Cells that were GFP negative, but could be stimulated to express GFP were selected. For the other similar cells, please see cat#s 100941-100948.
CELL TYPE:	Jurkat - T lymphocyte cell line
FREEZE MEDIUM:	FBS, 90%; DMSO, 10%.
GROWTH CHARACTERISTIC:	No special requirements, split 1:3 at 1 x 10^6 cells/ml. Cells grow in suspension, usually singly but some clumping has been noted.
PROPAGATION MEDIUM:	RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM, 0.3 mg/ml).
MORPHOLOGY:	Small, spherical cells in suspension. Morphology usually does not vary.
CONTRIBUTOR:	Dr. Eric Verdin.
REFERENCES:	Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22 :1868-1877, 2003. Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. <i>EMBO</i> J 20 :1726-1738, 2001.
ACKNOWLEDGMENT:	The following reagent was obtained by CFAR – NIBSC via the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J- Lat TAT-GFP Cells (clone #) from Dr. Eric Verdin. Also include the references above in any publication. Please ensure that you send us a copy of any papers Resulting from work using reagents acquired through CFAR, this can be by e-mail or printed copy.
Medicines and Healthcare	Resulting from work using reagents acquired through CFAR,